Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Beta-Blockers and Ovarian Cancer

What are the survival rates?

Use of nonselective beta-blockers during chemotherapy in patients with epithelial ovarian cancer (EOC) was associated with longer overall survival than patients without beta-blocker use in a study of 1,425 women with confirmed EOC. The impact of beta blockers was examined on the clinical outcomes of women (median age 63) with EOC, primary peritoneal, or fallopian tube cancers. In all, 269 patients received beta-blockers; 193 received beta-1-adrenergic receptor selective agents, and the remaining patients received nonselective beta antagonists. Researchers found:

• Median overall survival was 47.8 months for patients receiving any beta-blocker vs. 42.0 months for nonusers.

• Median overall survival based on beta-blocker receptor selectively was 94.9 months for those receiving nonselective beta-blockers vs. 38 months for those receiving beta-1 adrenergic receptor selective agents.

• Hypertension was associated with decreased overall survival compared with no hypertension across all groups.

Citation: Watkins JL, Thaker PH, Nick AM, et al. Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer. [Published online ahead of print August 24, 2015]. doi: 10.1002/cncr.29392.